New pill shows promise against Hard-to-Treat cancers
NCT ID NCT06993844
First seen Nov 01, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This study tests a new drug called ETX-636, taken as a pill, for people with advanced solid tumors (including breast cancer) that have a specific genetic change (PIK3CA mutation). The trial has two parts: first, finding a safe dose of ETX-636 alone or with another drug (fulvestrant), and then checking if it shrinks tumors. About 233 participants will join this early-stage study to see if the drug is safe and works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Luhe Hospital,Capital Medical University
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Beth Israel Deaconess Medical Center
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Carolina BioOncology Institute
RECRUITINGHuntersville, North Carolina, 28078, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact Phone: •••-•••-••••
Contact
-
Fred Hutchinson Cancer Center
RECRUITINGSeattle, Washington, 98109, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Fudan University Shanghai Cancer Hospital
RECRUITINGShanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Fujian Cancer Hospital
RECRUITINGFuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Hoag Memorial Hospital Presbyterian
RECRUITINGNewport Beach, California, 92663, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
NEXT
RECRUITINGFairfax, Virginia, 22031, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
START
RECRUITINGSan Antonio, Texas, 78229, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Shandong Cancer Hospital&Institute
RECRUITINGShandong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
-
UCSF Helen Diller Family Comprehensive Cancer Center
RECRUITINGSan Francisco, California, 94158, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yale University, Yale Cancer Center
RECRUITINGNew Haven, Connecticut, 06520, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ETX-636 (a targeted drug that blocks a specific cancer-driving protein, taken as a pill once daily, sometimes combined with fulvestrant)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors that have a specific genetic mutation (PIK3CA), potentially shrinking tumors or slowing their growth.
What could go wrong
This is a very early (first-in-human) trial, so the drug may not work as hoped or could cause unexpected side effects. Only a small number of participants will receive the drug initially, and results may not apply to all patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.